Imago BioSciences, Inc. ( IMGO) Stock. Should you Buy or Sell? $ 16.91
0.14 (0.82 %)
Imago BioSciences, Inc. Analysis
Updated on 10-09-2022| Symbol | IMGO |
| Price | $16.91 |
| Beta | 0.000 |
| Volume Avg. | $150.87 thousand |
| Market Cap | $570.57 M |
| 52 Week Range | $11.56 - $30.21 |
Imago BioSciences, Inc. opened the day at $16.91 which is +'0.82 % on yesterday's close. Imago BioSciences, Inc. has a 52 week high of $30.21 and 52 week low of $11.56, which is a difference of $18.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $570.57 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Imago BioSciences, Inc. for $570.57 M, it would take 15 years to get your money back. Imago BioSciences, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Imago BioSciences, Inc. Stock Forecast - Is Imago BioSciences, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -10.091 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Imago BioSciences, Inc.
| Price Book Value Ratio | 3.045 | Price To Book Ratio | 3.045 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -10.091 |
How liquid is Imago BioSciences, Inc.
| Current Ratio | 21.951 |
| Quick Ratio | 21.658 |
Debt
| Debt Ratio | 0.045 | Debt Equity Ratio | 0.047 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Imago BioSciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in three upcoming investor conferences.
Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021, at 10:40 a.m. ET.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
About Imago BioSciences, Inc.
Description :
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
